The current review analyzes the current pharmacologic approaches in cardiac surgery-associated acute kidney injury and renal replacement/support therapies.
INTRODUCTION
Cardiac surgery-associated acute kidney injury (CSA-AKI) occurs in up to 30% of patients who undergo cardiac surgery, with dialysis needed by about 3% of all surgical cases. Cardiac surgery is responsible for the highest risk of renal dysfunction with respect to general, thoracic, orthopedic, vascular, and urological surgery [1] [2] [3] [4] . Postoperative CSA-AKI may be caused by a variety of insults, including administration of toxins (e.g., antibiotics, diuretics, and contrast media), renal hypoperfusion, ischemia-reperfusion injury, and systemic inflammation with generation of oxidative stress. All these factors coact in the complex and multifactorial development of AKI [5] . Advanced age and multiple comorbidities (e.g., chronic renal, pulmonary and cardiac dysfunction, and diabetes mellitus), perioperative hypotension, low oxygen delivery during cardiopulmonary bypass (CPB), intraoperative use of vasoactive drugs, postoperative bleeding, as well as the combination of anemia and need of red blood cell transfusion are also important risk factors associated with CSA-AKI [1, 6, 7 in the use of contrast media and nephrotoxic drugs, and remote ischemic preconditioning) [7 & ,9
&& ,10], the incidence of renal complications remains high [9 && ,11]. In this complex clinical picture, there currently is no drug or therapeutic intervention able to resolve an established AKI. As the spectrum of AKI syndrome implies different severities of the disease and those are linearly correlated with clinical outcomes and mortality, several attempts have been described aiming to limit the progression of a diagnosed AKI. Unfortunately, current research has not fully answered to this extremely important demand, yet. This is likely due to the multifactorial nature of CSA-AKI and to the fact that a single strategy might not be adequate to address it, similar to what happens to polypharmacological treatment of multiresistant bacteria. In this context, even if renal replacement therapy (RRT) is considered the final approach to severe CSA-AKI, it should now be reappraised as a supportive therapy (with specific beneficial and harmful effects) rather than a simple 'renal substitution'.
The current review will focus on treatments currently available when AKI has occurred after cardiac surgery. General aspects on AKI management and treatment are behind this chapter, and the reader is referred to specific sources and guidelines [12 & ].
TEXT OF REVIEW

Hemodynamic management and nondialytic therapies
The management of intravenous fluid administration is a central factor for AKI treatment as optimal pressure and flow are necessary for tissue perfusion and cellular oxygenation. Traditionally, cardiac anesthesiologists have been attracted to colloids because of their potential capacity to expand the plasma volume over the crystalloid solutions. Nonetheless, colloids have not been demonstrated to be superior to crystalloids, and although theoretically they may improve maintenance of intravascular volume longer than crystalloids [13] , microvasculature injury and endothelial glycocalyx alterations, variably associated with cardiac surgery, actually limit volume expansion and may worsen tissue edema [14, 15] . Unfortunately, much of the data on colloids in cardiac surgery have been retracted [16] , and consistent concerns on AKI associated with hydroxyethyl starches (HESs) use have risen over the last years in cardiac surgery and critically ill patients [17] [18] [19] . In addition, albumin administration has been associated with increased rates of AKI in a recent retrospective cohort study including 984 patients undergoing on-pump cardiac surgery [20] . Differently, the use of crystalloid-balanced solutions and the limitation of HES administration have been shown to be associated with less CSA-AKI in off-pump surgery [21] . Based on available literature, caution should be paid on using colloids in cardiac surgery patients, and balanced crystalloid solutions could be recommended until concerns around starches and albumin have not been adequately addressed.
In addition to the debate on composition, volume management is frequently complicated by many pathophysiological alterations including endothelial glycocalyx permeability, right ventricular (RV) and/or left ventricular (LV) dysfunction, and valvular diseases [14] . All these factors may cause renal dysfunction and be simultaneously worsened by AKI. Specifically, the roles of LV dysfunction and increased central venous pressure (CVP) have been recognized as leading causes of AKI after cardiac surgery [22 && ]. Renal dysfunction is very common in patients with acute (and chronic) heart failure, and although it is widely accepted that renal perfusion (antegrade flow) is a foremost determinant of renal injury, many investigations have demonstrated a central relationship between renal dysfunction and venous congestion (backward failure), a condition in which the increased renal venous pressure causes an increase in renal subcapsular pressure reducing the glomerular filtration [23] [24] [25] . The difference between the arterial and venous blood pressure [26] portion of the Frank-Starling curve. This condition leads to the increase/optimization of the antegrade flow [cardiac output (CO)]. When ventricles are already performing along the flat portion of the curve (nonfluid responsiveness), fluid administration will eventually lead to unsuccessful improvement in CO, likely increase CVP, and cause detrimental renal venous congestion. Improving the identification of fluid-responders, dynamic measures based on heart-lung interaction in mechanically ventilated patients, such as pulse pressure variation or stroke volume variation [27 && ] surgery have demonstrated beneficial effects on patients' outcome including renal function in both cardiac and noncardiac settings [28, 29] . In addition, fluid responsiveness assessment based on variations of superior or inferior caval diameters in cardiac surgery patients could be of pivotal utility to avoid the administration of fluids in a system that has spent its volume capacitance and might eventually lead to venous hypertension and renal congestion [22 && ,30,31] . This is particularly important in the cardiac surgery patient considering that the RV contractility is frequently affected by surgery due to suboptimal myocardial protection during CPB, air embolism, and increased right afterload (e.g., pulmonary hypertension) [32] . Thus, prompt identification of RV dysfunction is of major importance as fluid management becomes challenging (nonfluid responder) and severe venous congestion is very likely [33, 34] , whereas rapid treatment of right heart dysfunction becomes a priority to reduce congestive kidney failure and favor recovery of renal function [25, 35, 36] . In addition, it has been demonstrated that a high CVP due to hypervolemia (that may be itself caused by oliguria) is much more detrimental on the kidney function than high CVP due to RV dysfunction without hypervolemia [22 && ]. Moreover, venous hypertension may limit the autonomic response to hypotension of the baroreceptors and the hemodynamic response to exogenous inotropes-vasopressors worsening the renal antegrade perfusion [22 && ,37] . In view of this complex scenario, the hemodynamic management of cardiac surgery patients with renal dysfunction should be directed to the entire injury factors: improvement of ventricular function [23] , avoidance of fluid overload without compromising right/left optimal preload [14] , pharmacological and nonpharmacological (mechanical ventilation) management of RV failure [38, 39] , and reduction of the RV afterload (pulmonary vascular resistances) while increasing ventricle systolic function. Management of acute RV dysfunction is challenging. LV preload may drop as well due to the interventricular interdependence [40 & ] and fully enters into the management of this form of low CO syndrome. On the contrary, in the case of fluid overload and insufficient response to diuretics, slow and controlled volume unloading, through continuous RRT, might be necessary [41] . A multipharmacological approach is frequently necessary: catecholamines (norepinephrine, epinephrine, and dobutamine) may improve RV function with direct inotropic effect but also by increasing systolic aortic pressure, thus improving RV myocardial perfusion. Phosphodiesterase III inhibitors (milrinone and enoximone), calcium sensitizers (levosimendan), and pulmonary vasodilators (inhaled nitric oxide, inhaled prostacyclin, and inhaled milrinone) may reduce RV afterload and improve its interaction with the pulmonary circulation and ventricular interdependence. On the other side, these drugs cause systemic hypotension, and coronary perfusion pressure may fall with threatening subendocardial ischemia. In this light, the careful combination of different drugs (e.g., phosphodiesterase III inhibitors and norepinephrine) could be suggested [41] . Specifically, levosimendan has been demonstrated to improve hemodynamics and renal function in patients undergoing cardiac surgery [42] [43] [44] . Few authors have recently faced the challenge of medical therapy of CSA-AKI, in addition to its hemodynamic management. An interesting prospective, double-blind, randomized, placebo controlled study was performed to evaluate the effects of human atrial natriuretic peptide (ANP) on AKI immediately following cardiac surgery [45] . The study, significantly underpowered, showed a decreased rate of postoperative RRT compared with placebo group in 61 patients with AKI following cardiac surgery randomized to receive a continuous infusion of either recombinant ANP (50 ng/kg/min) or placebo when serum creatinine (SCr) increased by more than 50% from baseline. The ANP infusion lasted until the SCr decreased below the baseline value at enrollment, the patient died, or the patients fulfilled predefined criteria for dialysis. RRT rate within 21 days from the enrollment, primary outcome of the study, was 21% in the ANP group and 47% in the placebo group (P ¼ 0.009). Similarly, the ANP group showed a significantly lower incidence of the combined end-point death-or-dialysis, compared with placebo (P ¼ 0.017). To clarify the role of ANP in prevention and treatment of AKI, Nigwekar et al. [46] [47] [48] [49] [50] [51] . Six hundred and sixty-seven patients with early CSA-AKI were randomized to receive fenoldopam (338 patients) or placebo (0.9% saline; 329 patients). The study was stopped for futility after an interim analysis performed by the study safety committee showed that 20 and 18% of patients allocated in the fenoldopam and placebo groups, respectively, received RRT (P ¼ 0.47), 30-day mortality 23 and 22% in the fenoldopam and placebo groups, respectively (P ¼ 0.86), and higher episodes of hypotension occurred in fenoldopam vs. placebo groups (26 vs. 15%, P ¼ 0.001). KDIGO guidelines suggest not using fenoldopam to prevent or treat AKI but randomized trials to treat AKI in cardiac and other high-risk settings may be con-
New potentially useful therapies could come from studies on the mesenchymal stem cells (MSCs). MSCs are adult, nonhematopoietic precursor cells mostly derived from human bone marrow and can differentiate into various mesenchymal tissues. They are currently considered a promising tool for therapeutic application for CSA-AKI [52, 53] . Animal studies have shown improvement of renal function in AKI after MSCs application in ischemia-reperfusion injury, cisplatinum, and glycerol experimental models [54, 55 && ]. Theoretical therapeutic advantages of MSCs are based on the observation that ischemia/reperfusion injury, a major cause of AKI and CSA-AKI, is characterized by acute tubular injury leading to rapid renal dysfunction [56] . Ischemia/reperfusion injury causes a complex inflammatory/oxidative stress, which may develop in fibroblast proliferation and extracellular matrix deposition [57] . In this context, MSCs' role in AKI treatment might depend on the secretion of promitotic, antiapoptotic, anti-inflammatory, and immunomodulatory factors [58] . Two different trials on MSCs have been recently completed in the recruitment: the first has been designed to determine the beneficial effects of allogeneic MSCs in patients who are at high risk of developing AKI after on-pump cardiac surgery (NCT00733876). Allogeneic MSCs have been administered to patients through a femoral artery catheter into the distal thoracic aorta. Even if the study is concluded, no definitive results are available yet but preliminary data demonstrate that at 16-month follow-up, kidney function is preserved and no case of dialysis has occurred [52, 55 && ]. The second trial is a phase II study on patients who have developed AKI after cardiac surgery (evaluation of kidney recovery after a single injection of allogeneic bone marrow-derived MSCs in patients who experience kidney injury within 48 h of their cardiac surgery; NCT01602328). The enrollment of 156 patients has been completed, and the results are not available yet.
Renal replacement therapy: the role of preemptive support
Approximately 2-6% of patients with CSA-AKI require RRT [54] . Different forms of RRT are now available for cardiac surgery patients, and many different clinical aspects may influence the choice of the RRT strategy. Importantly, KDIGO guidelines suggest using continuous RRT, rather than standard intermittent RRT, for hemodynamically unstable patients (grade 2B) [12 & ]. The optimal time to initiate RRT in CSA-AKI remains a debated area as precise criteria over globally urgent accepted indications (fluid overload not responder to diuretics, overt uremia, hyperkalemia, and severe metabolic acidosis) are missing so far. Due to promising results from small randomized controlled studies assessing the concept of early hemodialysis in CSA-AKI [59, 60] , great attention has been directed toward timing of RRT in terms of early or pre-emptive vs. late or standard [54] . Two hundred and three AKI patients treated with RRT after cardiac surgery were retrospectively evaluated in a multicenter study including 24 hospitals in Spain [61] . The patients were divided into early-RRT group (before the third postoperative day) or late-RRT group (after the third postoperative day). In-hospital mortality resulted significantly higher in the late-RRT group than early-RRT patients (80.4 vs. 53.2%; P < 0.001). In addition, the late group showed longer adjusted hospital stay (by 11.6 days) and higher increases in creatinine at discharge than early-RRT patients. According to the current Spanish study, RRT should be initiated as soon as possible when CSA-AKI with diuretic resistance occurs. Nonetheless, due to the limited number of related studies, the impact of early initiation of RRT on CSA-AKI outcome remains an open issue. Different results were observed by Crescenzi et al. in a similar population of postcardiac surgery patients. The early approach (urine output <0.5 ml/kg/h 6 h after surgery; 837 patients) was applied for 10 months and was followed by the application of the late approach (urine output <0.5 ml/kg/h >12 h after surgery; 821 patients) during the next 10 months [62] . Continuous veno-venous hemodiafiltration was prescribed at a dose of 30 ml/kg/h. The mortality rate was not statistically different between the early and late groups (3.8 and 2.3%, respectively; P ¼ 0.075). Similarly, no difference was observed in the ICU-stay (62.3 and 52.2 h in the early and late groups, respectively; P ¼ 0.065). Based on the observed results, the authors did not support the use of early RRT in CSA-AKI considering that early initiation may expose patients to the unnecessary risks of RRT without evident benefits. To better clarify the contrasting results on timing, Liu and et al. performed a systematic review and meta-analysis to investigate the impact of early vs. late RRT on mortality in patients with CSA-RRT [63] . Nine retrospective cohort studies and two randomized clinical trials including a total of 841 patients were included in the analysis. The 28-day mortality rate in the early-RRT group was lower (OR ¼ 0.29) and ICU stay was 3.9 days shorter. Before reaching definitive conclusions, it is important to consider that very heterogeneous studies have been included in the analysis. A recent interesting study aimed to investigate the impact of 'pre-emptive' RRT (in the absence of traditional indications of RRT) vs. 'standard' RRT on mortality in cardiac surgical patients [64] . Traditional indications were refractory metabolic acidosis (pH < 7.2), urine output less than 0.3 ml/kg/h for more than 24 h despite preload optimization, azotemia (SCr level >4 mg/dl), hyperkalemia more than 6.0 mmol/l, and evidence of fluid overload with pulmonary edema. The pre-emptive indications were AKI in the absence of traditional indications for RRT, persistence of hypotension more than 6 h despite preload optimization, and low probability of rapid renal recovery. RRT was applied in intermittent modality for 8-16 h per session. A total of 213 patients were included in the study (59 in the pre-emptive group and 154 in the standard group). The pre-emptive RRT group showed significantly lower mortality than the standard RRT group (33.9 vs. 51.9%, P ¼ 0.018). Secondary outcomes, including length of mechanical ventilation, ICU, and hospital stay, did not differ between the groups, whereas the pre-emptive RRT group had a significantly reduced time to recovery of renal function compared with the standard RRT group (15.34 vs. 22.88 days, P ¼ 0.022). The more interesting aspect of this study is that, differently from many others, the terms 'pre-emptive' and 'standard' instead of 'early' and 'late' reflected the timing of RRT initiation in addition to a strict temporal evolution of a clinical sign (e.g., the level of creatinine or the number of hours of oliguria). The pre-emptive definition can include patients who might recover renal function without the need of extracorporeal dialysis and potentially expose them to unwanted side-effects (bleeding due to heparin or metabolic acidosis due to global hypoperfusion in the case of hypotension after RRT start or acid-base derangements during citrate anticoagulation) [65, 66] . Supporters of pre-emptive renal support, however, consider that beneficial effects of RRT (prevention and effective treatment of fluid overload, improvement of lung and heart function, optimization of acid-base, and strong ion difference) significantly outweigh the drawbacks related to RRT. Furthermore, it is likely that a patient who recovers renal function without undergoing dialysis might have suffered from significant fluid overload before restoring its fluid balance homeostasis: no evidence is currently available on the fact that a potentially 'unnecessary' dialysis avoids renal function to recover as well (with the patient potentially achieving earlier optimized clinical conditions).
As a matter of fact, optimal timing for RRT can be considered an important aspect of severe AKI treatment and, likely, of its recovery. In view of this discussed and controversial topic, recent trials, although not specifically performed in cardiac surgery patients, have addressed this issue. A retrospective substudy of the prospective observational Finnish AKI [67] showed that crude 90-day mortality of patients with RRT started after 'classic indications' (hyperkalemia, acidosis, high blood urea levels, oliguria/anuria, and fluid overload) was significantly higher than in patients treated without a conventional indication ('pre-emptive' RRT). Moreover, patients with 'classic RRT' that started more than 12 h after the indication showed higher mortality compared with those who urgently underwent RRT. More recently, a single-center randomized trial, specifically designed to evaluate early initiation of RRT in critically ill patients with AKI, has been published by Zarbock et al. [68 && ]: the Early or deLAyed Initiation of RRT trial. This study showed that 90-day all-cause mortality is significantly reduced by early RRT start (39.3% in the early group and 54.7% in the delayed group; P ¼ 0.03). Unexpectedly, a similar (early vs. delayed RRT strategy) bigger multicenter randomized trial, the Artificial Kidney Initiation in Kidney Injury by Gaudry et al. [69 && ], failed to reach the benefit in overall survival at day 60 as primary outcome in earlystrategy group (58.5% in the early group and 49.7% in the delayed group; P ¼ 0.79). Noteworthy, similarly to the primary outcomes, the secondary outcomes were reached in Zarbock et al.'s study (e.g., duration of RRT, recovery of renal function, duration of mechanical ventilation, length of hospital and ICU stay, requirement of RRT at day 90, and decrease in IL-6 and IL-8 plasma concentration) suggesting further benefits in the early strategy, whereas the main secondary outcomes were not reached in Gaudry et al.'s study (e.g., dependence on RRT at day 28, dependence on RRT at day 60, catheter-related bloodstream infections, and hypophosphatemia). It is necessary to consider that significant differences in the various characteristics of the two studies exist and great attention before reaching any conclusion about early or late RRT benefits in patients with AKI should be paid. Different levels of severity and different definition of timing differentiate the two studies keeping them difficult/impossible to compare [70 & ,71 & ]. An ongoing trial, currently recruiting patients, the Standard vs. Accelerated Initiation of RRT in AKI multicenter trial (NCT02568722), will probably provide us with some more information on this uncertain aspect of RRT. It is possible that studies trying to uncritically establish starting a renal support sooner or later, on the basis of predefined criteria, will hardly end up with successful results: in the opinion of the writing authors, it would be better to personalize (every aspect of) RRT (including timing), focusing on single patients and carefully examining every single case at the bedside, possibly with the help of a multidisciplinary team.
On [72] . The authors found that among the variables significantly associated with higher mortality risk was a CVVH duration of less than 50 h over 72 h (>50 h; OR ¼ 0.009, 95% CI 0.04-0.93; P ¼ 0.01). This study suggests that RRT strategy based on long-lasting CVVH could improve patients' outcome and should be continued as long as possible during the first 3 days. KDIGO guidelines suggest discontinuing RRT when it is no longer required, either because intrinsic kidney function has recovered to the point that it is adequate to meet patient needs or because RRT is no longer consistent with the goals of care (not graded) and also suggests not using diuretics to enhance kidney function recovery or to reduce the duration or frequency of RRT (grade 2B) [12 & ].
CONCLUSION
Intense and promising research is ongoing on the treatment of established CSA-AKI. No specific pharmacologic strategy for CSA-AKI resolution can be currently recommended outside clinical research, even if some successful pharmacologic approaches have been recently described. It is clear that no single shot might be the correct therapy for AKI occurring after cardiac surgery. Instead, a holistic approach should be warranted to our patients, including careful preoperative patient selection, risk stratification, accurate prevention, timely diagnosis, and aggressive intervention when early AKI signs develop. In this view, hemodynamic optimization (with wise fluid administration and vasoactive drug choice) has a crucial role in the initial treatment of AKI patients. RRT remains a mainstay tool in severe cases to prevent further injury and, in expert hands, may facilitate recovery of renal function. Timing and modalities to improve RRT delivery need to be further investigated. 
